Abbvie Inc.

Kimberly-Clark Worldwide, Inc.

Abbott Laboratories Corporation

Abbvie Deutschland Gmbh and Co Kg

Abbott Gmbh & Co Kg

Enrico L Digiammarino

Chung-Ming Hsieh

Ulrich Ebert

Jijie Gu

Martin Schmidt

Reinhold Mueller

Volker Nimmrich

John E Harlan

Gerard B Fox

Ralf Loebbert

Zhen Wu

Feng Luo

Charles W Hutchins

Rosann Marie Kaylor

Kaiyuan Yang

Ning Wei

Jeffrey Eldon Fish

Kenton L Longenecker

Jieyi Wang

Shawn Ray Feaster

Edward B Reilly

Mark Anderson

Chibueze Obi Chidebelu-Eze

Debra Chao

Archana Thakur

James M Takeuchi

Qian Zhang

Russell A Judge

David A Egan

The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

Prolactin receptor binding proteins and uses thereof

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

A lateral flow assay device includes a housing, and a test strip disposed within the housing having a membrane with a detection region and a collection region. A sample meter includes a first end for absorption of a test sample, and a storage section that receives and stores at least a component of the test sample. An opening in the housing is sized for insertion of the sample meter into the housing such that the storage section of the sample meter is disposed adjacent the collection region of the membrane. The test sample component is transferable from the storage section to the collection region for subsequent migration to the detection region. An activatable isolation mechanism is provided within the housing and is disposed so as to isolate portions of the sample meter storage section upon activation thereof such that a defined length of the storage section is presented to the collection region of the membrane.

Lateral flow assay device

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Growing community of inventors

Lindenhurst, IL, United States of America

Enrico L Digiammarino